Acute Respiratory Distress Syndrome Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Acute Respiratory Distress Syndrome Treatment Market is segmented By Treatment (Drug Class, Device) By Route of Administration (Oral, Parenteral) By Sales Channel (Distribution Channel, End User) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

Global Acute Respiratory Distress Syndrome Treatment Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2031 growing at a CAGR of YY% during the forecast period 2024-2031.

Acute respiratory distress syndrome is a severe and life-threatening condition characterized by widespread inflammation in the lungs that leads to respiratory failure. It is marked by the sudden onset of severe respiratory symptoms and a significant decrease in oxygen levels in the blood.

Acute respiratory distress syndrome typically develops within a few hours to a few days after the onset of an underlying injury or illness. The mechanism involves an inflammatory response that damages the delicate lung tissue. This inflammation causes increased permeability of the alveolar-capillary membrane, allowing fluid to leak into the alveoli.

Market Scope

For more details on this report – Request for Sample

Market Dynamics

Increasing incidence of sepsis

The increasing prevalence of sepsis acts as a significant driver for market growth. Sepsis triggers a systemic inflammatory response as the body attempts to fight the infection. This response can become dysregulated which leads to widespread inflammation throughout the lungs.

For instance, according to the World Health Organization Report 2023, there were 48.9 million cases and 11 million sepsis-related deaths worldwide which accounted for almost 20% of all global deaths. Also, almost half of all global sepsis cases occurred among children, with an estimated 20 million cases and 2.9 million global deaths in children under 5 years of age.

Additionally, according to the National Institute of Health Report 2022, nine observational studies involving 324,020 Chinese patients (9,587 patients with sepsis) were analyzed. Four hospital-wide studies involving 301,272 patients showed pooled prevalence and mortality of 3.8% and 26% respectively. Hence, the increasing incidence of sepsis can lead to the main cause of acute respiratory distress syndrome.

Furthermore, significant growth drivers such as the increasing awareness regarding ARDS, rising geriatric population, and increasing acute lung injuries are expected to drive the market in the forecast period.

Lack of specific therapies

The lack of specific therapies for Acute Respiratory Distress Syndrome (ARDS) is a significant challenge. ARDS is a syndrome with diverse causes, including sepsis, pneumonia, trauma, and others. The underlying pathophysiology can vary which leads to differences in the response to treatment. Also, the limited understanding hinders the development of targeted therapies aimed at specific molecular pathways. Thus, the above factors can hamper the market growth.

Segment Analysis

The global acute respiratory distress syndrome treatment market is segmented based on treatment, route of administration, sales channel and region.

The corticosteroids segment accounted for approximately 56.8% of the market share 

The corticosteroids segment is expected to hold the largest market share over the period forecast. Acute respiratory distress syndrome involves an inflammatory response in the lungs. Corticosteroids, with their potent anti-inflammatory effects can theoretically help in modulating the excessive inflammation associated with ARDS.

The timing of corticosteroid administration is crucial and the early administration of corticosteroids during the inflammatory phase can have different implications compared to late administration in the fibroproliferative phase. 

Methylprednisolone and dexamethasone are both corticosteroids that have been studied in the context of Acute Respiratory Distress Syndrome (ARDS). These medications belong to the class of glucocorticoids and have anti-inflammatory and immunosuppressive properties. The use of methylprednisolone in ARDS has been studied in clinical trials and has been associated with improved oxygenation and a reduction in markers of inflammation. 

Geographical Analysis

North America is expected to hold a significant position in the global acute respiratory distress syndrome treatment market share

The global acute respiratory distress syndrome treatment market is segmented into North America, Europe, Asia Pacific, South America, Middle East and Africa. 

North America has maintained a significant market proportion due to factors such as the increasing prevalence of ARDS, clinical trials, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.

For instance, according to the National Institute of Health Report 2023, the incidence of ARDS in the United States ranges from 64.2 to 78.9 cases per 100,000 person-years. Twenty-five percent of ARDS cases are initially classified as mild, and 75% as moderate or severe. 

Additionally, in July 2023, Aqualung Therapeutics received FDA Clearance to proceed with the P2A PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) patients. Hence, due to the above factors, it is expected to drive the region’s growth.

COVID-19 Impact Analysis 

The COVID-19 pandemic has had a significant impact on the global acute respiratory distress syndrome treatment market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, drug launches, and consultations worldwide. With the outbreak of the pandemic, many treatment centers faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the acute respiratory distress syndrome treatment market was moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include AbbVie Inc., Pfizer Inc., Par Pharmaceutical Inc., Merit Pharmaceutical, Narang Medical Limited, Beijing Aeonmed Co. Ltd., Shenzhen Mindray Bio-Medical Electronic Co. Ltd, Medtronic Plc., Drägerwerk AG & Co. KGaA and ONY Biotech Inc among others.

Key Developments

• In September 2023, Chrysalis received FDA approval to initiate clinical trials with Chrysalin (TP508). TP508 is a natural regenerative peptide that accelerates tissue repair and revascularization while modulating the inflammatory response.

Why Purchase the Report?

• To visualize the global acute respiratory distress syndrome treatment market segmentation based on treatment, route of administration, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of global acute respiratory distress syndrome treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global acute respiratory distress syndrome treatment market report would provide approximately 61 tables, 58 figures, and 185 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies